A Phase 1 Open-label, Radiolabeled, Single-dose Study To Investigate The Metabolism Of [14c]Lorlatinib (Pf-06463922) In Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Lorlatinib (Primary)
- Indications Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 25 Jul 2017 Status changed from not yet recruiting to recruiting.
- 29 Jun 2017 Planned initiation date changed from 29 Jun 2017 to 5 Jul 2017.
- 14 Jun 2017 New trial record